1,2,3,4,6-Penta-O-galloyl-β-d-glucopyranose inhibits angiogenesis via inhibition of capillary morphogenesis gene 2

Lorna M. Cryan, Lauren Bazinet, Kaiane Habeshian, Shugeng Cao, Jon Clardy, Kenneth A. Christensen, Michael S. Rogers

Research output: Contribution to journalArticle

Abstract

Capillary morphogenesis gene 2 (CMG2) is a transmembrane extracellular matrix binding protein that is also an anthrax toxin receptor. We have shown that high-affinity CMG2 binders can inhibit angiogenesis and tumor growth. We recently described a high-throughput FRET assay to identify CMG2 inhibitors. We now report the serendipitous discovery that PGG (1,2,3,4,6-penta-O-galloyl- β-d-glucopyranose) is a CMG2 inhibitor with antiangiogenic activity. PGG is a gallotannin produced by a variety of medicinal plants that exhibits a wide variety of antitumor and other activities. We find that PGG inhibits CMG2 with a submicromolar IC50 and it also inhibits the migration of human dermal microvascular endothelial cells at similar concentrations in vitro. Finally, oral or intraperitoneal administration of PGG inhibits angiogenesis in the mouse corneal micropocket assay in vivo. Together, these results suggest that a portion of the in vivo antitumor activity of PGG may be the result of antiangiogenic activity mediated by inhibition of CMG2.

Original languageEnglish (US)
Pages (from-to)1940-1945
Number of pages6
JournalJournal of Medicinal Chemistry
Volume56
Issue number5
DOIs
StatePublished - Mar 14 2013
Externally publishedYes

Fingerprint

Rubiaceae
Morphogenesis
Genes
Hydrolyzable Tannins
Extracellular Matrix Proteins
Medicinal Plants
Inhibitory Concentration 50
Carrier Proteins
Endothelial Cells
Skin
Growth
Neoplasms

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Cryan, L. M., Bazinet, L., Habeshian, K., Cao, S., Clardy, J., Christensen, K. A., & Rogers, M. S. (2013). 1,2,3,4,6-Penta-O-galloyl-β-d-glucopyranose inhibits angiogenesis via inhibition of capillary morphogenesis gene 2. Journal of Medicinal Chemistry, 56(5), 1940-1945. https://doi.org/10.1021/jm301558t

1,2,3,4,6-Penta-O-galloyl-β-d-glucopyranose inhibits angiogenesis via inhibition of capillary morphogenesis gene 2. / Cryan, Lorna M.; Bazinet, Lauren; Habeshian, Kaiane; Cao, Shugeng; Clardy, Jon; Christensen, Kenneth A.; Rogers, Michael S.

In: Journal of Medicinal Chemistry, Vol. 56, No. 5, 14.03.2013, p. 1940-1945.

Research output: Contribution to journalArticle

Cryan, LM, Bazinet, L, Habeshian, K, Cao, S, Clardy, J, Christensen, KA & Rogers, MS 2013, '1,2,3,4,6-Penta-O-galloyl-β-d-glucopyranose inhibits angiogenesis via inhibition of capillary morphogenesis gene 2', Journal of Medicinal Chemistry, vol. 56, no. 5, pp. 1940-1945. https://doi.org/10.1021/jm301558t
Cryan, Lorna M. ; Bazinet, Lauren ; Habeshian, Kaiane ; Cao, Shugeng ; Clardy, Jon ; Christensen, Kenneth A. ; Rogers, Michael S. / 1,2,3,4,6-Penta-O-galloyl-β-d-glucopyranose inhibits angiogenesis via inhibition of capillary morphogenesis gene 2. In: Journal of Medicinal Chemistry. 2013 ; Vol. 56, No. 5. pp. 1940-1945.
@article{061622696d3842de93721247d3bf9bf1,
title = "1,2,3,4,6-Penta-O-galloyl-β-d-glucopyranose inhibits angiogenesis via inhibition of capillary morphogenesis gene 2",
abstract = "Capillary morphogenesis gene 2 (CMG2) is a transmembrane extracellular matrix binding protein that is also an anthrax toxin receptor. We have shown that high-affinity CMG2 binders can inhibit angiogenesis and tumor growth. We recently described a high-throughput FRET assay to identify CMG2 inhibitors. We now report the serendipitous discovery that PGG (1,2,3,4,6-penta-O-galloyl- β-d-glucopyranose) is a CMG2 inhibitor with antiangiogenic activity. PGG is a gallotannin produced by a variety of medicinal plants that exhibits a wide variety of antitumor and other activities. We find that PGG inhibits CMG2 with a submicromolar IC50 and it also inhibits the migration of human dermal microvascular endothelial cells at similar concentrations in vitro. Finally, oral or intraperitoneal administration of PGG inhibits angiogenesis in the mouse corneal micropocket assay in vivo. Together, these results suggest that a portion of the in vivo antitumor activity of PGG may be the result of antiangiogenic activity mediated by inhibition of CMG2.",
author = "Cryan, {Lorna M.} and Lauren Bazinet and Kaiane Habeshian and Shugeng Cao and Jon Clardy and Christensen, {Kenneth A.} and Rogers, {Michael S.}",
year = "2013",
month = "3",
day = "14",
doi = "10.1021/jm301558t",
language = "English (US)",
volume = "56",
pages = "1940--1945",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "5",

}

TY - JOUR

T1 - 1,2,3,4,6-Penta-O-galloyl-β-d-glucopyranose inhibits angiogenesis via inhibition of capillary morphogenesis gene 2

AU - Cryan, Lorna M.

AU - Bazinet, Lauren

AU - Habeshian, Kaiane

AU - Cao, Shugeng

AU - Clardy, Jon

AU - Christensen, Kenneth A.

AU - Rogers, Michael S.

PY - 2013/3/14

Y1 - 2013/3/14

N2 - Capillary morphogenesis gene 2 (CMG2) is a transmembrane extracellular matrix binding protein that is also an anthrax toxin receptor. We have shown that high-affinity CMG2 binders can inhibit angiogenesis and tumor growth. We recently described a high-throughput FRET assay to identify CMG2 inhibitors. We now report the serendipitous discovery that PGG (1,2,3,4,6-penta-O-galloyl- β-d-glucopyranose) is a CMG2 inhibitor with antiangiogenic activity. PGG is a gallotannin produced by a variety of medicinal plants that exhibits a wide variety of antitumor and other activities. We find that PGG inhibits CMG2 with a submicromolar IC50 and it also inhibits the migration of human dermal microvascular endothelial cells at similar concentrations in vitro. Finally, oral or intraperitoneal administration of PGG inhibits angiogenesis in the mouse corneal micropocket assay in vivo. Together, these results suggest that a portion of the in vivo antitumor activity of PGG may be the result of antiangiogenic activity mediated by inhibition of CMG2.

AB - Capillary morphogenesis gene 2 (CMG2) is a transmembrane extracellular matrix binding protein that is also an anthrax toxin receptor. We have shown that high-affinity CMG2 binders can inhibit angiogenesis and tumor growth. We recently described a high-throughput FRET assay to identify CMG2 inhibitors. We now report the serendipitous discovery that PGG (1,2,3,4,6-penta-O-galloyl- β-d-glucopyranose) is a CMG2 inhibitor with antiangiogenic activity. PGG is a gallotannin produced by a variety of medicinal plants that exhibits a wide variety of antitumor and other activities. We find that PGG inhibits CMG2 with a submicromolar IC50 and it also inhibits the migration of human dermal microvascular endothelial cells at similar concentrations in vitro. Finally, oral or intraperitoneal administration of PGG inhibits angiogenesis in the mouse corneal micropocket assay in vivo. Together, these results suggest that a portion of the in vivo antitumor activity of PGG may be the result of antiangiogenic activity mediated by inhibition of CMG2.

UR - http://www.scopus.com/inward/record.url?scp=84875158359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875158359&partnerID=8YFLogxK

U2 - 10.1021/jm301558t

DO - 10.1021/jm301558t

M3 - Article

C2 - 23394144

AN - SCOPUS:84875158359

VL - 56

SP - 1940

EP - 1945

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 5

ER -